NO20033862L - Fremgangsmåte for prevensjon eller terapi av inflammatoriske eller autoimmune lidelser ved administrering av integrin-alfa-beta3-antagonisteri kombinasjonmed andre profylaktiske eller terapeutiske midler - Google Patents

Fremgangsmåte for prevensjon eller terapi av inflammatoriske eller autoimmune lidelser ved administrering av integrin-alfa-beta3-antagonisteri kombinasjonmed andre profylaktiske eller terapeutiske midler

Info

Publication number
NO20033862L
NO20033862L NO20033862A NO20033862A NO20033862L NO 20033862 L NO20033862 L NO 20033862L NO 20033862 A NO20033862 A NO 20033862A NO 20033862 A NO20033862 A NO 20033862A NO 20033862 L NO20033862 L NO 20033862L
Authority
NO
Norway
Prior art keywords
beta3
integrin
prophylactic
inflammatory
therapy
Prior art date
Application number
NO20033862A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033862D0 (no
Inventor
Christine Dingivan
Ronald Wilder
Original Assignee
Medimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Inc filed Critical Medimmune Inc
Publication of NO20033862D0 publication Critical patent/NO20033862D0/no
Publication of NO20033862L publication Critical patent/NO20033862L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20033862A 2001-03-02 2003-09-01 Fremgangsmåte for prevensjon eller terapi av inflammatoriske eller autoimmune lidelser ved administrering av integrin-alfa-beta3-antagonisteri kombinasjonmed andre profylaktiske eller terapeutiske midler NO20033862L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27309801P 2001-03-02 2001-03-02
US31632101P 2001-08-31 2001-08-31
US34691801P 2001-10-19 2001-10-19
US35842402P 2002-02-19 2002-02-19
PCT/US2002/006679 WO2002070007A1 (fr) 2001-03-02 2002-03-04 Prevention ou traitement de troubles inflammatoires ou auto-immuns par l'administration d'antagonistes de l'integrine $g(a)v$g(b)¿3?

Publications (2)

Publication Number Publication Date
NO20033862D0 NO20033862D0 (no) 2003-09-01
NO20033862L true NO20033862L (no) 2003-10-31

Family

ID=27501069

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033862A NO20033862L (no) 2001-03-02 2003-09-01 Fremgangsmåte for prevensjon eller terapi av inflammatoriske eller autoimmune lidelser ved administrering av integrin-alfa-beta3-antagonisteri kombinasjonmed andre profylaktiske eller terapeutiske midler

Country Status (12)

Country Link
US (2) US20020168360A1 (fr)
EP (1) EP1372720A4 (fr)
JP (1) JP2004536786A (fr)
CN (1) CN1507354A (fr)
AU (1) AU2002306651B2 (fr)
CA (1) CA2439852A1 (fr)
HU (1) HUP0303340A2 (fr)
IL (1) IL157706A0 (fr)
MX (1) MXPA03007878A (fr)
NO (1) NO20033862L (fr)
NZ (1) NZ528076A (fr)
WO (1) WO2002070007A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
EP1113497A3 (fr) * 1999-12-29 2006-01-25 Texas Instruments Incorporated Boîtier à semi-conducteur, avec l'impédance du conducteur sélectionnée au cour de l'assemblage
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US20060135463A1 (en) * 2002-09-27 2006-06-22 Wood Christopher B Methods and compositions for the treatment of lupus using clofarabine
AU2003276988B2 (en) 2002-09-27 2009-11-05 Bioenvision, Inc. Methods and compositions for the treatment of autoimmune disorders using clofarabine
CA2514653A1 (fr) * 2003-01-30 2004-08-12 Medimmune, Inc. Utilisations d'antagonistes de l'integrine alphavbeta3
US20080025989A1 (en) * 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
AU2004213053C1 (en) 2003-02-20 2009-07-16 Seagen Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
WO2005026209A2 (fr) 2003-09-11 2005-03-24 Critical Therapeutics, Inc. Anticorps monoclonaux diriges contre hmgb1
CA2540730C (fr) 2003-10-01 2012-08-21 Merck Patent Gmbh Antagonistes d'integrine alfavbeta3 et alfavbeta6 en tant qu'agents antifibrosants
JP2007526022A (ja) * 2003-10-24 2007-09-13 メドトロニック・インコーポレーテッド 炎症誘発性媒介物質の産生を減弱することによって神経性障害を処置する技法
US7371381B2 (en) 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
US7691379B2 (en) 2004-04-12 2010-04-06 Medimmune, Llc Anti-IL-9 antibody formulations
US7351739B2 (en) 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
KR101314461B1 (ko) 2004-05-12 2013-10-07 더 브리검 앤드 우먼즈 하스피털, 인크. 감염 치료를 위한 겔솔린의 용도
WO2006012415A2 (fr) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Derives de proteine rage
WO2006034334A2 (fr) * 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Analogue peptidique capable d'ameliorer la stimulation d'une reponse ctl specifique des gliomes
US8337838B2 (en) * 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
JP5222559B2 (ja) * 2004-10-15 2013-06-26 シアトル ジェネティックス， インコーポレイテッド 癌および免疫障害の処置および予防のための抗ｃｄ７０抗体ならびにその使用
SG142305A1 (en) * 2004-10-19 2008-05-28 Aventis Pharma Inc Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'- trifluoromethylphenyl)-amide for treating inflammatory bowel disease
US20060253100A1 (en) 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
EP2422811A2 (fr) 2004-10-27 2012-02-29 MedImmune, LLC Modulation d'une spécificité d'anticorps par adaptation sur mesure de son affinité a une antigène apparente
PL3321359T3 (pl) 2005-04-11 2021-06-28 Horizon Pharma Rheumatology Llc Wariantowe postacie oksydazy moczanowej i ich zastosowanie
EP1899376A2 (fr) 2005-06-16 2008-03-19 The Feinstein Institute for Medical Research Anticorps diriges contre hmgb1 et fragments de ceux-ci
GB0512225D0 (en) * 2005-06-16 2005-07-27 Univ Sheffield Immunoglobulin molecules
CA2613512A1 (fr) 2005-06-23 2007-01-04 Medimmune, Inc. Formulations d'anticorps possedant des profils d'agregation et de fragmentation optimises
SG169361A1 (en) 2005-11-01 2011-03-30 Abbott Biotech Ltd Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
PT3279663T (pt) 2006-03-15 2021-09-24 Brigham & Womens Hospital Inc Utilização de gelsolina para o diagnóstico e tratamento de doenças inflamatórias
ES2455167T3 (es) * 2006-06-01 2014-04-14 The Regents Of The University Of California Método de terapia combinada y formulación
AU2007272970C1 (en) 2006-07-11 2013-01-10 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
DE102006033837A1 (de) * 2006-07-21 2008-01-31 Medac Gesellschaft für klinische Spezialpräparate m.b.H Konzentrierte Methotrexat-Lösungen
BRPI0715115A2 (pt) * 2006-08-03 2013-06-04 Vaccinex Inc anticorpo monoclonal isolado, molÉcula de Ácido nucleico isolada, vetor de expressço, cÉlula hospedeira, mÉtodos para tratar uma doenÇa, e para produzir um anticorpo monoclonal isolado, uso do anticorpo monoclonal isolado, e, composiÇço farmacÊutica
CA3177366A1 (fr) 2006-08-10 2008-02-21 Roy C. Levitt Therapie locale de troubles inflammatoires des voies aeriennes inferieures avec des inhibiteurs de cytokine proinflammatoire
CA3153438C (fr) 2006-09-07 2024-03-12 Scott & White Memorial Hospital Methodes et compositions a base de conjugues toxine diphterique-interleukine 3
ES2634263T3 (es) 2008-01-25 2017-09-27 The General Hospital Corporation Usos de diagnóstico terapéuticos de gelsolina en insuficiencia renal
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
WO2010042433A1 (fr) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combinaison d'anticorps cd137 et d'anticorps ctla-4 pour le traitement de maladies prolifératives
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
EP3482768A1 (fr) 2009-06-25 2019-05-15 Horizon Pharma Rheumatology LLC Procédés et kits pour prédire le risque de réaction de perfusion et perte induite par anticorps de la réponse par surveillance de l'acide urique sérique pendant une thérapie uricase pégylée
US20110150856A1 (en) * 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
ES2722799T3 (es) 2010-08-24 2019-08-16 Univ Pittsburgh Commonwealth Sys Higher Education Vacunas contra el cáncer de cerebro basadas en el péptido alfa 2 del receptor de interleuquina-13
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
CA2854233C (fr) 2011-11-04 2020-05-12 Zymeworks Inc. Structure d'anticorps heterodimerique stable comprenant des mutations dans le domaine fc
EP2828664B1 (fr) 2012-03-19 2018-09-26 Stemline Therapeutics Inc. Méthodes de traitement et de surveillance de l'état du cancer
EP2847230B1 (fr) 2012-05-10 2020-08-12 Zymeworks Inc. Constructions hétéromultimères de chaînes lourdes d'immunoglobulines comprenant des mutations dans le domaine fc
EP4321218A3 (fr) 2012-05-16 2024-04-24 Stemline Therapeutics, Inc. Vaccins contre le cancer ciblant des cellules souches cancéreuses
CN102827281B (zh) * 2012-08-03 2014-05-28 无锡傲锐东源生物科技有限公司 抗cd2蛋白单克隆抗体及其用途
SG11201605316VA (en) * 2013-12-29 2016-07-28 Curelab Oncology Inc Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases
US20160066601A1 (en) * 2014-09-06 2016-03-10 Ashley G. Herr Edible 3d printer filament
EP3573658A4 (fr) * 2017-01-30 2021-07-21 Janssen Biotech, Inc. Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
WO2020160325A1 (fr) * 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Réduction de l'immunogénicité de la pegloticase
CN113874392A (zh) 2019-03-28 2021-12-31 丹尼斯科美国公司 工程化抗体
WO2020236797A1 (fr) * 2019-05-21 2020-11-26 Novartis Ag Domaines de cd58 variants et leurs utilisations
JP2022534020A (ja) 2019-05-23 2022-07-27 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
WO2021202473A2 (fr) 2020-03-30 2021-10-07 Danisco Us Inc Anticorps modifiés

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4658019A (en) * 1979-04-26 1987-04-14 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells
US5851526A (en) * 1985-04-19 1998-12-22 Ludwig Institute For Cancer Research Methods of treating colon cancer utilizing tumor-specific antibodies
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US5306620A (en) * 1987-07-08 1994-04-26 The Scripps Research Institute Antibodies that bind to a ligand-induced binding site on integrin and induce integrin activation
CA2000048A1 (fr) * 1988-10-03 1990-04-03 Edward F. Plow Peptides et anticorps inhibant la liaison integrine-ligand
US5149780A (en) * 1988-10-03 1992-09-22 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5360716A (en) * 1988-10-24 1994-11-01 Otsuka Pharmaceutical Co., Ltd. Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α
US5223395A (en) * 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
US5147638A (en) * 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5498694A (en) * 1989-05-25 1996-03-12 La Jolla Cancer Research Foundation Peptides of the cytoplasmic domain of integrin
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
US5644034A (en) * 1989-08-07 1997-07-01 Peptide Technology Ltd. Tumour necrosis factor binding ligands
EP0939121B2 (fr) * 1989-09-12 2007-12-26 AHP Manufacturing B.V. Protéines liant le TNF
US5196511A (en) * 1989-12-01 1993-03-23 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5262520A (en) * 1989-12-01 1993-11-16 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5136021A (en) * 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
DE4006269A1 (de) * 1990-02-28 1991-08-29 Max Planck Gesellschaft Antikoerper gegen den tumor-nekrosefaktor-rezeptor
US5830678A (en) * 1990-10-30 1998-11-03 Fred Hutchinson Cancer Research Center Method for identifying a target peptide that modulates the binding of epinectin ligand to integrin receptors
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
JPH06506195A (ja) * 1991-01-14 1994-07-14 ニューヨーク　ユニバシテイ サイトカイン誘導タンパク質、ｔｓｇ−１４、そのためのｄｎａコード化およびその使用
ATE153768T1 (de) * 1991-01-15 1997-06-15 Bayer Ag Ergänzung von oberflächenrezeptoren
MX9203138A (es) * 1991-03-12 1992-09-01 Biogen Inc Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
US5547853A (en) * 1991-03-12 1996-08-20 Biogen, Inc. CD2-binding domain of lymphocyte function associated antigen 3
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5310874A (en) * 1991-05-03 1994-05-10 The Scripps Research Institute Integrin α subunit cytoplasmic domain polypeptides and antibodies
US5334380A (en) * 1991-09-27 1994-08-02 Board Of Regents, The University Of Texas System Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
AU680411B2 (en) * 1992-04-03 1997-07-31 Genentech Inc. Antibodies to alphavbeta3 integrin
US5478725A (en) * 1992-06-12 1995-12-26 University Of Pennsylvania αv β3 integrin as a predictor of endometriosis
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
ATE155043T1 (de) * 1992-10-08 1997-07-15 Kennedy Inst Of Rheumatology Behandlung von autoimmun- und entzundungskrankheiten
US5705481A (en) * 1992-11-06 1998-01-06 Merck Patent Gesellschaft Mit Beschrankter Haftung Cyclopeptides
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
US5951983A (en) * 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
US5730979A (en) * 1993-03-05 1998-03-24 Universite Catholique Delouvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
DE4310643A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US5523209A (en) * 1994-03-14 1996-06-04 The Scripps Research Institute Methods for identifying inhibitors of integrin activation
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
DE4415310A1 (de) * 1994-04-30 1995-11-02 Merck Patent Gmbh Cyclopeptide
AU698393B2 (en) * 1994-06-24 1998-10-29 Immunex Corporation Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
DK0719859T3 (da) * 1994-12-20 2003-10-20 Merck Patent Gmbh Anti-alfa V-integrin monoklonalt antistof
US5780426A (en) * 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
US5767071A (en) * 1995-06-07 1998-06-16 Ixsys Incorporated Sevenmer cyclic peptide inhibitors of diseases involving αv β3
US5817750A (en) * 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
US5817457A (en) * 1996-02-07 1998-10-06 Ma Bioservices, Inc. Methods and kits for detecting viral reverse transcriptase activity in a sample using an acidic pH or an elevated temperature
DE69736812T2 (de) * 1996-11-27 2007-08-09 Bristol-Myers Squibb Pharma Co. Neue integrin rezeptor antagonisten
US6590079B2 (en) * 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US20010011125A1 (en) * 1997-01-30 2001-08-02 William D. Huse Anti-alpha v beta 3 recombinant human antibodies, nucleic acids encoding same and methods of use
US6596850B1 (en) * 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US5968741A (en) * 1997-04-11 1999-10-19 Cedars-Sinai Medical Center Methods of diagnosing a medically resistant clinical subtype of ulcerative colitis
PT973550E (pt) * 1997-04-11 2003-01-31 Searle & Co Anticorpos antagonistas anti-integrina avb3
US6171787B1 (en) * 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease
US6096707A (en) * 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
WO1999026945A1 (fr) * 1997-11-26 1999-06-03 Du Pont Pharmaceuticals Company 1,3,4-THIADIAZOLES ET 1,3,4-OXADIAZOLES UTILISES COMME ANTAGONISTES DE αvβ¿3?
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
AU748621B2 (en) * 1998-08-13 2002-06-06 Merck & Co., Inc. Integrin receptor antagonists
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
CN1192796C (zh) * 1999-02-12 2005-03-16 斯克里普斯研究学院 联合应用抗血管生成和免疫治疗以治疗肿瘤和转移的方法
JP2001029067A (ja) * 1999-05-14 2001-02-06 Kanegafuchi Chem Ind Co Ltd 抗原特異的細胞傷害抑制性細胞の誘導方法
US6531580B1 (en) * 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
CA2386230C (fr) * 1999-10-06 2009-05-05 Basf Aktiengesellschaft Modulateurs de voies de signalisation associees a la cytokine et antagonistes du recepteur .alpha.v.beta.3 d'integrine pour therapie combinatoire
ATE403437T1 (de) * 1999-12-14 2008-08-15 Genentech Inc Lfa-1 antagonisten und tnf-alpha antagonisten zur behandlung von rheumatoiden arthritis

Also Published As

Publication number Publication date
US20090053234A1 (en) 2009-02-26
US20020168360A1 (en) 2002-11-14
CA2439852A1 (fr) 2002-09-12
MXPA03007878A (es) 2004-07-08
EP1372720A4 (fr) 2006-07-26
NO20033862D0 (no) 2003-09-01
IL157706A0 (en) 2004-03-28
HUP0303340A2 (hu) 2003-12-29
JP2004536786A (ja) 2004-12-09
WO2002070007A1 (fr) 2002-09-12
EP1372720A1 (fr) 2004-01-02
CN1507354A (zh) 2004-06-23
AU2002306651B9 (en) 2002-09-19
AU2002306651B2 (en) 2007-12-13
NZ528076A (en) 2005-09-30

Similar Documents

Publication Publication Date Title
NO20033862L (no) Fremgangsmåte for prevensjon eller terapi av inflammatoriske eller autoimmune lidelser ved administrering av integrin-alfa-beta3-antagonisteri kombinasjonmed andre profylaktiske eller terapeutiske midler
NO20053678D0 (no) Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser
AU2002322478A1 (en) Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
NO20044054L (no) Administrering av midler for behandling av betennelse
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
EP1622589A4 (fr) Compositions, cibles, methodes et dispositifs pour le traitement de troubles oculaires et peri-oculaires
HK1109867A1 (en) Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders
DK1660057T3 (da) Kombinationsterapi til behandling af neovaskulære øjenlidelser
NO20041882L (no) Fremgangsmater for behandling av okulare neovaskulaere sykdommer.
NO20025286D0 (no) Aminosubstituerte dibenzotiofenderivater for behandling av forstyrrelser forÕrsaket av NP YP reseptoren
IL157320A0 (en) Rapid-onset medicament for the treatment of sexual dysfunction
NI200600319A (es) Antagonistas de ccr2 de sal cuaternaria
WO2005000298A3 (fr) Inhibiteurs de p-38
EP1352897A3 (fr) Dérivés d'adamantane pour le traitement de maladies inflammatiores, immunes et cardiovasculaires
NO20034864D0 (no) Preparat for behandling av legemiddelindusert forstoppelse med 15-keto-prostaglandiner
NO20034311D0 (no) CCR5-antagonister for behandling av AIDS
DK1764111T3 (da) Vaginalt indgivne anti-dysrytmi midler til behandling af uterin dysrytmi
AU2003213787A1 (en) Compositions and methods for the treatment of anorectal disorders
NO20043085L (no) Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet
NO20016246D0 (no) Selektiv iGluR5 reseptorantagonist for behandling av migrene
NO20034232D0 (no) Anvendelse av glukokortikoid-reseptor-spesifikke antagonister ved behandling av stresslidelser
NO20033417D0 (no) Anvendelse av CD23-antagonister for behandling av neoplastiske forstyrrelser
NO20034123L (no) Fremgangsmåte for behandling av brennstoff
DK1344526T3 (da) Midler til forebyggelse/behandling af inflammatoriske luftvejslidelser
NO20041024D0 (no) Anvendelse av BIBN4096 i kombinasjon med andre antimigrenelegemidler for behandling av migrene

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application